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OBJECTIVE—Neuropathy is a frequent and severe complica-
tion of diabetes. Multiple metabolic defects in type 2 diabetic
patients result in oxidative injury of dorsal root ganglia (DRG)
neurons. Our previous work focused on hyperglycemia clearly
demonstrates induction of mitochondrial oxidative stress and
acute injury in DRG neurons; however, this mechanism is not the
only factor that produces neuropathy in vivo. Dyslipidemia also
correlates with the development of neuropathy, even in pre-
diabetic patients. This study was designed to explore the contri-
bution of dyslipidemia in neuropathy.
RESEARCH DESIGN AND METHODS—Mice (n  10) were
fed a control (10% kcal %fat) or high-fat (45% kcal %fat) diet to
explore the impact of plasma lipids on the development of
neuropathy. We also examined oxidized lipid–mediated injury in
cultured DRG neurons from adult rat using oxidized LDLs
(oxLDLs).
RESULTS—Mice on a high-fat diet have increased oxLDLs and
systemic and nerve oxidative stress. They develop nerve conduc-
tion velocity (NCV) and sensory deﬁcits prior to impaired glucose
tolerance. In vitro, oxLDLs lead to severe DRG neuron oxidative
stress via interaction with the receptor lectin-like oxLDL receptor
(LOX)-1 and subsequent NAD(P)H oxidase activity. Oxidative stress
resulting from oxLDLs and high glucose is additive.
CONCLUSIONS—Multiple metabolic defects in type 2 diabetes
directly injure DRG neurons through different mechanisms that all
result in oxidative stress. Dyslipidemia leads to high levels of
oxLDLs that may injure DRG neurons via LOX-1 and contribute to
the development of diabetic neuropathy. Diabetes 58:2376–2385,
2009
O
ur work is focused on understanding the mech-
anisms that lead to diabetic neuropathy and
developing rational therapeutic interventions.
Hyperglycemia clearly leads to peripheral
nerve injury through the development of systemic and
neuronal oxidative stress (1–6). An emerging idea is that
dyslipidemia also contributes to the development of diabetic
neuropathy (7,8). Lipid proﬁles are commonly abnormal
early in the course of type 2 diabetes in a temporal pattern
that correlates with the presence of diabetic neuropathy, and
we recently reported that elevated triglyceride levels predict
a more rapid disease course (9,10). In addition, several
large-scale trials of type 2 diabetic patients point to early
dyslipidemia as a major independent risk factor for the
development of diabetic neuropathy (11).
In experimental diabetes, the complex etiology of dia-
betic neuropathy is difﬁcult to explore due to the multiple
sources of nerve injury, including hyperglycemia, ad-
vanced glycation end products, systemic oxidative stress,
and altered growth factor availability (12). Furthermore,
lipid proﬁles of mice differ from human patients in that the
majority of plasma cholesterol is transported in HDL and
LDL levels are constitutively low (13). Mice with geneti-
cally increased plasma cholesterol have accelerated ath-
erosclerosis that renders them unsuitable for neuropathy
studies (13). Several studies (14–16) explored the role of a
high-fat diet in the development of both diabetes and
diabetic complications. Susceptibility to neuropathy is
mouse strain dependent; the constitution of the diet is
another important factor. One study (17) suggests that a
high-fat diet produces neuropathy independent of hyper-
glycemia, and the present study explores a potential
mechanism of high-fat–induced neuropathy.
Because high-fat diets increase plasma LDLs and pre-
diabetes is associated with systemic oxidative stress (18),
we proposed that oxidized LDLs (oxLDLs) will be elevated
in mice fed a high-fat diet. Furthermore, we predicted that
increased oxLDLs may produce dorsal root ganglia (DRG)
neuron injury through binding the lectin-like oxLDL recep-
tor (LOX)-1 in a similar manner to vascular endothelial
cells (19) and renal tubular cells (20). The activation of
LOX-1 on endothelial cells leads to intracellular oxidative
stress and inﬂammation and a feed-forward cycle of injury
in diabetes, since both oxLDLs and glucose increase
LOX-1 expression (21,22).
In this study, we used high-fat feeding in the C57/BL6
mouse strain using a 45-kcal %fat (mostly from lard) diet.
We demonstrate morphological and functional evidence of
neuropathy prior to loss of glucose regulation in agree-
ment with clinical ﬁndings (10,23,24). This is associated
with signiﬁcant increases in plasma oxLDLs. We assessed
oxLDL-mediated injury in cultured DRG neurons from
adult rats. oxLDLs directly lead to oxidative stress and
injury in DRG neurons via LOX-1. DRG neuron injury is
partially induced via activation of NAD(P)H oxidase. We
conclude that diet-induced plasma oxLDLs can produce
neuron injury and may be a contributing factor in the
development of neuropathy in pre-diabetes or diabetes.
RESEARCH DESIGN AND METHODS
High-fat–fed mice. C57/BL6 mice (The Jackson Laboratory, Bar Harbor, ME)
at 3 weeks of age were placed on either control AIN5003 (10% kcal %fat) or
high-fat (45% kcal %fat) diet D12451i from Research Diets (New Brunswick,
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content. Blood glucose was tested every 4 weeks following a 6-h fast. One
drop of tail blood was analyzed using a standard glucometer (no. 6 strips,
OneTouch Proﬁle; Lifescan, Milpitas, CA). Glucose tolerance tests were
performed by measuring blood glucose 5, 15, 30, 60, and 120 min after gavage
administration of a glucose bolus. Nerve conduction velocity (NCV) studies
were performed after 12 and 34 weeks and neuropathy phenotyping (see
below) at termination at 34 weeks. GHb was measured using the Helena
Laboratories test kit, Glyco-Tek Afﬁnity Column Method (catalog no. 5351), as
previously described (25,26). Insulin was measured by radioimmunoassay in
the Michigan Diabetes Research and Training Center (MDRTC) Chemistry
Core.
Nerve conduction studies. Hindpaw thermal latency and NCV were mea-
sured per our published protocols (2,12,26–28) and in compliance with
protocols established by the Animal Models of Diabetic Complications Con-
sortium (http://www.amdcc.org). Mice were anesthetized with 30/0.75 mg/kg
ketamine/acepromazine by peritoneal injection, and body temperatures were
maintained at 32–34°C using a heating pad.
Tissue harvest. Mice were killed with an overdose of pentobarbital 34 weeks
after initiation of control or high-fat diets. Sciatic nerves were harvested and
submerged in ice-cold antioxidant buffer A (100 mol/l diethylene tetramino
pentaacetic acid, 50 mol/l butylated hydroxyl toluene, 1% [vol/vol] ethanol,
10 mmol/l 3-amino-1,2,4-triazole, and 50 mmol/l sodium phosphate buffer, pH
7.4), rapidly frozen by immersion in liquid nitrogen, and stored at 80°C until
analysis. A blood sample (100–300 l) was collected into K3 EDTA vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ) and centrifuged at 100g for 15
min at 4°C. Plasma was collected and stored at 80°C.
Intraepidermal nerve ﬁber density. Foot pads were collected from the
hindpaw plantar surface; postﬁxed in Zamboni’s (2% PFA, 1% picric acid in 0.1
mol/l PBS) solution overnight; rinsed in 5, 10, and 20% sucrose in 50 mmol/l
sodium phosphate buffer; cryoembedded; sectioned (35 m); and processed
for PGP 9.5 immunohistochemistry (1:2,000; Chemicon, Temecula, CA) per
our previous work (25,26,28). The data are presented as the number of ﬁbers
per millimeters squared across one entire papilla.
Plasma lipid proﬁling. Plasma samples from ﬁve mice per group were
pooled to produce two pools per group, and each pool was run ﬁve times on
fast-protein liquid chromatography then the fractions assayed for cholesterol
and triglycerides. These assays were performed as previously published by the
Mouse Metabolic Phenotyping Center Core at the University of Washington,
Seattle (29). LDLs were isolated from mouse plasma by discontinuous density
ultracentrifugation as described previously (30). A total of 200 l plasma was
overlaid with normal saline (d  1.006 kg/l) and ultracentrifuged for 60 min at
541,000gmax at 4°C. After removal of VLDLs from the top, the density was
adjusted with solid KBr to d  1.300 kg/l, then overlaid with normal saline and
ultracentrifuged for 60 min at 541,000gmax at 4°C. LDLs were removed by
aspiration of the top layer. The sample was desalted using a PD10 column
(Sephadex G-25M; Amersham) and eluted with 0.01 mol/l PBS (pH 7.4).
Hydroxyoctadecadienoic acid, dityrosine, and nitrotyrosine levels. Hy-
droxyoctadecadienoic acid (HODE), dityrosine, and nitrotyrosine were mea-
sured in plasma, sciatic nerve, and isolated LDLs, as described previously
(31–33). HODEs were quantiﬁed in lipid extracts by reverse-phase C-18
high-performance liquid chromatography (250  4.6 mm, particle size 5 m,
Ultrasphere column; Beckman). Amino acids were analyzed by reverse-phase
high-performance liquid chromatography (Jasco HPLC column, C-18 column
250  4.6 mm, particle size 5 m, ODS Ultrasphere; Beckman). The identity
and quantity of the compounds were conﬁrmed by identical retention time on
standard curves with authentic o,o’-dityrosine and tyrosine by monitoring
absorbance at 460 nm. Nitrotyrosine was quantiﬁed by isotope dilution mass
spectrometry as described previously (33).
Adult DRG neuron cultures. DRG were collected from killed adult female
Sprague-Dawley rats and dissociated in 0.2% collagenase for 30 min followed
by 1% trypsin for 15 min. Cells were seeded on collagen-coated plates in
DMEM:F-10, 50:50, containing 1  B27 additives, 40 mol/l 2-Deoxy-5-
ﬂuorouridine (FUDR), 7 mol/l aphidicolin, and 1,000 units/ml penicillin/
streptomycin/neomycin. Cells were refed on day 2, and experiments were
performed on day 3. In this media, the basal glucose concentration is 5.7
mmol/l. For high-glucose experiments, 20 mmol/l glucose is added to the
media, yielding a total of 25.7 mmol/l. For oxLDL experiments, a dose curve
from 1 to 100 g/ml was selected, based on other in vitro studies (34–37).
From LDL isolation, we estimate that there was 300–400 g/ml LDL protein
in the mouse plasma. The amount of LDL protein was not signiﬁcantly
different between control and high-fat mice, but oxidation markers were 1.6-
to 24-fold higher in high-fat compared with control mice (Table 1). This
plasma LDL concentration is 10–30 times higher than the 30 g/ml dose
oxLDL used in the in vitro experiments. Control experiments were always
performed with nonoxidized LDLs, and these did not produce the cellular
responses of oxLDLs (data not shown).
Measurement of reactive oxygen species. MitoSOX and dihydroethidium
(DHE) (Molecular Probes, Eugene, OR) are cell-permeable probes that
ﬂuoresce in the presence of superoxide. The probes are used as previously
described (25,38,39). Mean red ﬂuorescence per well is read at 485 nm
excitation and 590 nm emission (Fluoroskan Ascent II plate reader; Lab-
Systems, Helsinki, Finland).
Total radical antioxidant potential. Total radical antioxidant potential
(TRAP) is determined by a luminometric method per our published protocols
(1,25). DRG neurons were lysed in ultrapure water and tested for the ability to
prevent 2,2-azobis(amidinopropane) dihydrochloride (ABAP)-induced lumi-
nescence in the presence of electrochemiluminescence reagent (Amersham,
PA). The data were normalized to the untreated control samples (100%).
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FIG. 1. Mild neuropathy after 12 weeks of high-fat diet. Following 12
weeks of high-fat or control diet, weight (A), blood glucose (B),
hindpaw withdrawal latency (C), and sciatic NCV (D) were assessed.
n  10/group. *P < 0.05 vs. control diet.
TABLE 1
Oxidative stress measures in plasma, LDLs, and sciatic nerve
Control
mice
High-fat
mice
HODE (pmol/mg protein)
Plasma 97  8 119  6*
LDL cholesterol 116  14 193  10*
Sciatic nerve 117  10 169  16*
Dityrosine (mol/mol tyrosine)
Plasma 24  23 6  3*
LDL cholesterol 23  2 546  91*
Sciatic nerve 3  18  1*
Nitrotyrosine (mol/mol tyrosine)
Plasma 84  8 147  22*
LDL cholesterol 90  11 144  57*
Sciatic nerve 3  11 7  4*
Data are means  SE. Lipid and protein peroxidation were assessed
by reverse-phase high-performance liquid chromatography. HODE,
dityrosine, and nitrotyrosine were all signiﬁcantly increased in
plasma (n  10), sciatic nerve (n  10), and isolated LDL (n  2).
*P  0.05.
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lysates is assessed as previously described (1). The rate of luminescence
increase in the presence or absence of apocynin was calculated to give a
measure of superoxide generation by NAD(P)H oxidase activity (lumines-
cence units/min).
Fragmentation of genomic DNA. TdT-mediated dUTP-biotin nick-end label-
ing (TUNEL) staining is used to detect cell death in cultured DRG neurons
(10,18,29). Samples are ﬁxed in 4% paraformaldehyde, labeled with digoxyge-
nin-dUTP, then stained with horseradish peroxidase–conjugated anti-digoxy-
genin antibody using a kit according to the manufacturer’s instructions
(Intergen, Gaithersburg, MD).
Immunohistochemistry. DRG neurons were ﬁxed in 4% paraformaldehyde in
0.1 mol/l PBS solution for 5 min. Primary antibodies were applied in 0.1 mol/l
PBS/1% Triton  100/5% serum for 16 h at 4°C. Cells were washed for 3  for
10 min each in PBS, and then species-speciﬁc secondary antibody was
conjugated to AlexaFluor 594, (Molecular Probes, Eugene, OR) diluted 1:1,000
in 0.1 mol/l PBS containing 1% Triton  100 and 5% serum. After a further 1 h
at room temperature, cells were washed 3  for 10 min each in PBS. For
nitrotyrosine, the primary was antibody 244 (10 g/ml; Upstate Biologicals,
Lake Placed, NY). Fluorescence was quantitated in the ﬂuorescent plate
reader at 485 excitation and 590 emission. For LOX-1, the primary was Ox-LDL
R-1 (Y-21), from Santa Cruz sc11653, diluted 1:100. Immunoﬂuorescence was
examined on an Olympus Fluoview inverted microscope.
Western blotting. Western blotting was performed per our previous studies
(1–3) with 40 g protein/lane, separated on a 12.5% polyacrylamide gel.
Caspase 3. After 5-h exposure to 20 mmol/l excess glucose, one coverslip
from each dose was treated with ﬂuorescent CaspaTag reagent per manufac-
turer’s protocol (Chemicon, San Francisco, CA) and assessed in the ﬂuores-
cence plate reader per previous studies (1,25).
Statistical analysis. In cell culture studies, all experimental paradigms were
performed in triplicate on three separate occasions with different cell cul-
tures, giving a ﬁnal n  9 for each data point. In mouse studies, there were 10
mice per group for all in vivo studies. Lipid proﬁling was performed three
times on each of two pools of plasma per group (n  2). Data analyses were
performed using Prism, version 3 (GraphPad Software). Assumptions about
the Gaussian distribution of data and rules for transformation of nonnorma-
tive data were made as previously described (28). Comparison of dependent
variables was performed using factorial ANOVA with 95% CIs. All measure-
ments were made by an observer blinded to the experimental condition. Bar
graphs illustrate the mean  SE.
RESULTS
High-fat–fed mice develop neuropathy. Following 12
weeks on a high-fat diet, mice were modestly heavier than
mice on a control diet (28.9  1.4 g compared with 25.4 
0.5 g) (Fig. 1A) but did not have increased fasting blood
glucose (Fig. 1B). Despite the lack of evidence for glucose
intolerance, the mice displayed evidence of neuropathy.
The latency of hindpaw response to a heat stimulus was
signiﬁcantly increased (P  0.05) (Fig. 1C), and the sciatic
NCV was slowed in the high-fat mice (P  0.05) (Fig. 1D).
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FIG. 2. Neuropathy and impaired glucose tolerance after 34 weeks on high-fat diet. Complete phenotyping after 34 weeks on control (Ctrl) or
high-fat (HF) diet was performed. The ﬁgure displays the glucose tolerance test (A), weight (B), plasma insulin (C), GHb (D), sural NCV (E),
sciatic NCV (F), hindpaw withdrawal latency (G), and IENFD (H). *P < 0.05 vs. the control diet group. In all panels, n  10. A: , control; ,
high fat. I: Representative IENFD images from one control-fed and one high-fat–fed sample. Bar  50 m; d  dermis, e  epidermis. White dots
indicate nerve ﬁbers counted. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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sural NCV) showed no difference between control and
high-fat diet–fed mice (not shown).
By 34 weeks, mice displayed glucose intolerance with
signiﬁcantly higher blood glucose levels 15 min after
applying the glucose bolus, and this difference remained at
2 h (Fig. 2A). Similarly, body weight, plasma insulin, and
GHb were all signiﬁcantly increased in the high-fat group
compared with those on the control diet (Fig. 2B–D),
indicating frank diabetes in the high-fat mice. NCV mea-
sures in sural (P  0.05) and sciatic (P  0.01) nerves were
both decreased in the high-fat mice compared with control
diet mice (Fig. 2E–F). Sensory neuropathy was evident in
the high-fat mice through decreased response to a heat
stimulus on the hindpaw (Fig. 2G) and decreased intraepi-
dermal nerve ﬁber density (IENFD) in the hindpaw skin
(Fig. 2H–I).
Oxidative stress was assessed in plasma, isolated LDLs,
and sciatic nerves (Table 1). Plasma lipids were signiﬁ-
cantly oxidized, as evidenced by increased HODE, and
plasma proteins were both oxidized (dityrosine) and ni-
trosylated (nitrotyrosine) in high-fat–fed mice compared
with mice on the control diet. We also measured these
oxidation markers in LDLs isolated from the mice to
conﬁrm the elevation of oxLDLs (Table 1). Next, we
compared plasma lipid proﬁles between the two groups of
mice. HDL were increased and the peak shifted slightly left
in the high-fat–fed group, indicating uptake of cholesterol.
There was also a shift in the high-fat–fed group to increase
the population of LDLs, and these contain signiﬁcantly
elevated triglycerides. Also, a peak of VLDLs is evident in
the high-fat mice but absent in the control diet mice (Fig.
3A). There were signiﬁcant increases in the levels of
triglycerides associated with the LDL/VLDL samples in the
high-fat–fed mice, as well as free triglycerides in the
high-fat–fed mice only (Fig. 3B). Together, data in Table 1
and Fig. 3 conﬁrm that high-fat feeding increases plasma
lipids and oxLDLs.
DRG neurons express LOX-1. We demonstrated that
DRG neurons express the receptor for oxLDL, LOX-1, by
immunocytochemistry and Western blotting. The Western
blot demonstrates that three isoforms of LOX-1 are
present in adult DRG neurons (Fig. 4A). The 48-kDa
glycosylated form is most highly expressed in the neurons.
This isoform is glycosylated for transport to the plasma
membrane and is considered the active isoform (40).
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FIG. 3. Plasma lipid proﬁles in the plasma at 34 weeks. Pooled plasma samples (two pools per group, each pool analyzed three times) were
subjected to fractionation by FPLC; then cholesterol (A) and triglycerides (B) were measured in each fraction. The graph shows the means  SE
for n  2 pools/group. f regular diet; Œ, high-fat diet.
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led to an increase in the 48-kDa isoform (Fig. 4B). Immu-
nocytochemistry in control DRG neurons conﬁrms that
LOX-1 is present on the neurons (arrows) and not only on
residual Schwann cells in the cultures (Fig. 4C).
oxLDLs generate oxidative stress in DRG neurons via
LOX-1. To deﬁne the mechanisms of oxidized lipid–
induced neuropathy, we explored the effects of oxLDLs on
adult DRG neurons in culture. We found a dose-dependent
increase in mitochondrial superoxide after a 1-h exposure
to oxLDLs (Fig. 5A). Above 30 g/ml oxLDLs there was a
signiﬁcant increase in mitochondrial superoxide that was
additive to the levels produced by high glucose. Using a
second probe, DHE, we conﬁrmed that a portion of
oxLDL-induced superoxide involved the mitochondria
(Fig. 5B). We demonstrate that, similar to MitoSOX oxida-
tion, DHE oxidation increases above 30 g/ml oxLDL and
that 50% of this signal is blocked in the presence of the
mitochondrial uncoupler carbonylcyanide-p-triﬂuorome-
thoxyphenylhydrazone (FCCP) (2.5 mol/l). This dose of
FCCP leads to loss of mitochondrial membrane potential
and ATP generation, and the data suggest that 50% of the
DHE signal is produced via mitochondrial electron trans-
fer chain generation of superoxide. Preloading the cells
with 	-lipoic acid (100 mol/l) also blocked DHE oxida-
tion at 10 and 30 mol/l doses. 	-Lipoic acid decreased
(P  0.05) but did not completely prevent DHE oxidation
in response to 100 mol/l oxLDL (Fig. 5B). Conﬁrmation
that generation of superoxide leads to oxidative stress in
this system was achieved using assays for TRAP (Fig. 5C)
and cellular nitrotyrosine (Fig. 5D). Using a single dose
and time point where there was substantial oxidative
stress in the MitoSOX assay, exposure to 30 g/ml oxLDL
for 3 h signiﬁcantly decreased the antioxidant potential of
DRG neurons by 
40%. Doses as low as 10 g/ml oxLDL
increased nitrotyrosine over 24 h in the DRG neurons (Fig.
5D), and 100 g/ml oxLDL achieved nitrotyrosine levels
similar to high glucose. oxLDL-induced, but not high-
glucose–induced, nitrotyrosine was blocked by preincu-
bating the DRG neurons with a LOX-1 neutralizing
antibody (100 mg/ml).
oxLDL-/LOX-1–induced DRG neuron injury involves
NAD(P)H oxidase. We next examined DRG neuron in-
jury via activation of caspase 3 (Fig. 6A) and degradation
of nuclear DNA (Fig. 6B). Activation of caspase 3 after 5 h
was signiﬁcantly increased by at least threefold in the
presence of high glucose or 10, 30, or 100 g/ml oxLDL.
Pretreatment with LOX-1 neutralizing antibody (100 mg/
ml) signiﬁcantly blocked oxLDL-induced, but not glucose-
induced, caspase 3 activation. The NAD(P)H oxidase
inhibitor apocyanin (1 mol/l) signiﬁcantly blocked
caspase 3 activation with 10 g/ml oxLDL but decreased
with increasing concentrations of oxLDLs. This may be
due to the dose of apocyanin being too low to block high
levels of NAD(P)H oxidase activity, but higher doses of
apocyanin induce oxidative stress and cell injury (data not
shown). The antioxidant 	-lipoic acid (100 mol/l) efﬁ-
ciently blocked caspase 3 activation induced by both high
glucose and doses of oxLDLs up to 100 mol/l.
The TUNEL assay was performed after 24 h to deter-
mine the total cell death caused by high-glucose or oxLDL
treatments. High glucose produces 60  4% DRG neuron
death after 24 h (Fig. 6B). This death is completely blocked
by the antioxidant 	-lipoic acid (100 mol/l), consistent
with high-glucose injury in these cells via mitochondrial
oxidative stress, as we previously published in embryonic
DRG (Fig. 4A). Glucose-induced injury was not altered by
anti–LOX-1 or by apocyanin.
At 10 g/ml oxLDL, there was an 10% increase in
TUNEL over 24 h. There was no signiﬁcant effect of
antioxidant or apocyanin, but blocking LOX-1 signiﬁcantly
decreased TUNEL to control levels (Fig. 6B). A total of 30
g/ml oxLDL increased TUNEL to 60% and 100 g/ml to
70%. All three inhibitors—apocyanin, anti–LOX-1, and an-
tioxidant—signiﬁcantly decreased oxLDL-induced cell
death to approaching control levels (P  0.01).
Conﬁrmation that oxLDL/LOX-1 interaction acti-
vates NAD(P)H oxidase. Next, we examined the activa-
tion of NAD(P)H oxidase at the 1- and 3-h time points (Fig.
7). Both p47 and gp91 were localized in the cell soma in
untreated control DRG neurons, but 3 h subsequent to
exposure to oxLDLs, labeling was also identiﬁed along the
dendrites and the intensity of staining was increased (Fig.
7A). The activity of NAD(P)H oxidase was signiﬁcantly
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cytochemistry (C) after 3 days in culture. A: A total of 40 mg protein
from untreated control (C) cultures in lane 1 display the glycosylated
48-kDa isoform of LOX-1 that is predicted to be at the cell surface. The
lower–molecular weight precursor (40 kDa) and nonglycosylated (32
kDa) isoform are also present. Exposure to high glucose (G) (20
mmol/l added, total 25.7 mmol/l glucose) or 1 g/ml oxLDL for3hd i d
not alter LOX-1 expression. A total of 5, 10, or 30 mg/ml oxLDL for 3 h
increased the level of the 48-kDa isoform, and the two higher doses
appear to decrease the lower–molecular weight forms. , a positive
control peptide based on the 40 kDa predicted precursor form of
LOX-1. B: Densitometry was performed on three replicates of the
representative blot shown in A. Mean pixel densities for the 48-kDa
band are normalized against actin. The graph shows the means  SE.
*P < 0.05 vs. the untreated control. C: A representative image of
untreated DRG neurons is shown. White arrows indicate neurons
labeled for LOX-1. Bar  50 m. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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showed previously (1). Following exposure to 30 g/ml
oxLDL, NAD(P)H oxidase activity increased by 100% but
was decreasing toward control levels by 3 h (Fig. 7B). By
Western blotting, the p47 subunit was increased in DRG
neurons exposed to high glucose or oxLDLs (30 g/ml) for
3 h. The gp91 antibody did not produce a clearly deﬁned
band on Western blots (not shown).
DISCUSSION
In this report, we conﬁrm that high-fat feeding in mice
produces neuropathy and increased tissue and systemic
oxidative stress prior to the development of frank diabe-
tes. We postulated that these metabolic changes would
generate oxLDLs and that these could contribute to neu-
ronal injury mechanisms. We demonstrate that DRG neu-
rons express the oxLDL receptor LOX-1 and that
activation of this receptor in vitro leads to NAD(P)H
oxidase activity that injures DRG neurons via generation
of oxidative stress.
After 12 weeks on a high-fat diet, weight was modestly
increased while fasting blood glucose remained normal.
The hindpaw latency was increased and sciatic NCV
decreased, consistent with peripheral neuropathy. Previ-
ous studies (14,41,42) established that a high-fat diet leads
to type 2 diabetes in mice. These studies focused on the
mechanisms leading to insulin resistance, although one
study (43) examined the consequences of a high-fat diet on
the onset of nephropathy and one (17) on neuropathy. No
previous study has shown that a high-fat (speciﬁcally high
cholesterol) diet leads to NCV deﬁcits and reduced hind-
paw withdrawal response prior to impaired glucose toler-
ance. Our current data suggest that high-fat–induced
neuronal deﬁcits may precede the development of
diabetes.
By 34 weeks on the high-fat diet, the mice displayed
impaired glucose tolerance, a signiﬁcant increase in
plasma insulin levels, and an increase in GHb. These
increases are small compared with mice with frank type 2
diabetes, where the plasma insulin may be elevated four-
fold and GHb by several percent, but the extent of
neuropathy is comparable (26). This provides supporting
evidence for a role for dyslipidemia in the development of
neuropathy. Clinical studies support this ﬁnding. In the
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FIG. 5. High glucose and oxLDL induce oxidative stress in adult DRG neurons. After 3 days in culture, oxidative stress assays were performed
in cultured DRG neurons. A: DRG neurons were exposed to increasing concentrations of oxLDL in the presence of basal (5.7 mmol/l) or high (25.7
mmol/l) glucose for 1 h, then loaded with MitoSOX for 15 min. n  9, *P < 0.01 vs. control (basal glucose, 0 g/ml oxLDL). f, basal glucose; u,
high glucose. B: DRG neurons were exposed to increasing concentrations of oxLDL alone or in the presence of the mitochondrial uncoupler FCCP
(2.5 mol/l) or the antioxidant -lipoic acid (LA) (100 mol/l) for 1 h, then loaded with DHE for 15 min. n  9; *P < 0.01, P < 0.05 vs. control.
C: TRAP was assessed in untreated DRG neurons and those exposed to 30 g/ml oxLDL for 3 h, n  3, *P < 0.01. D: Nitrotyrosine ﬂuorescence
was assessed 24 h following exposure to high glucose or increasing concentrations of oxLDL in the presence or absence of LOX-1–neutralizing
antibody (100 mg/ml). f, none; , anti–LOX-1. n  9, *P < 0.01 vs. untreated control; †P < 0.01 vs. no antibody.
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diabetic neuropathy at baseline, hypertension, serum lip-
ids, and BMI were each independently associated with the
risk of developing diabetic neuropathy during a 7-year
follow-up period. Of these risk factors, dyslipidemia was
closely linked with the onset and progression of diabetic
neuropathy (44). In parallel, we recently reported that
dyslipidemia, not hyperglycemia, was more closely corre-
lated with neuropathy progression in 427 trial participants
(10).
We demonstrate not only that the high-fat diet produced
dyslipidemia, with high levels of HDL and LDL cholesterol
and triglycerides, but also that LDLs and other circulating
lipids and proteins are oxidized. Oxidatively modiﬁed
proteins and lipids are toxic to complication-prone tissues,
such as renal tubules (20) and the retina (45). In particular,
oxLDLs mediate vascular injury via interaction with LOX-1
on endothelial cells (46). This led us to postulate that
oxLDLs may injure DRG neurons.
We report strong expression of LOX-1 on the adult DRG
neurons by Western blotting and immunocytochemistry.
Next, we characterized the effects of high glucose and
oxLDLs on DRG neuron oxidative stress. Both insults lead
to mitochondrial superoxide formation, the key mediator
of DRG neuron injury in high glucose (1,2,38,47). The
effects of high glucose and oxLDLs on mitochondrial
superoxide were additive. Furthermore, antioxidant po-
tential is depleted over time by oxLDLs. Using a neutral-
izing antibody to LOX-1, we demonstrate that the effects of
oxLDLs are largely mediated via the LOX-1 receptor. This
protection has been shown for vascular injury in dyslipi-
demia (48) but not previously for neurons. Our data
suggest that multiple metabolic deﬁcits in dyslipidemia
and early diabetes combine to produce oxidative stress
and accelerate the onset and progression of neuropathy.
These data strongly argue for an antioxidant component to
therapies for diabetic neuropathy (49). Our work also
raises the interesting question of how obesity, immobility,
and the metabolic syndrome contribute to neuropathy.
High glucose or oxLDLs insults increased DRG neuron
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nuclear DNA degradation. The injury produced by either
stressor was blocked by the antioxidant 	-lipoic acid.
These data support the consensus that pathways leading
to cellular injury in diabetes (mainly shown for hypergly-
cemia to date) converge upon oxidative stress. Antioxi-
dant therapies remain the most promising strategy for
diabetic neuropathy, but clearly greater understanding of
the long-term application of antioxidant therapy needs to
be explored.
We also found that inhibition of NAD(P)H oxidase could
block oxLDL-induced, but not high-glucose–induced, in-
jury. Supporting evidence that oxLDLs led to NAD(P)H
oxidase activity was obtained by observing subunit ex-
pression and localization and by measuring apocyanin-
inhibitable NADPH oxidation. Thus, NAD(P)H oxidase
activation and subsequent generation of superoxide is the
primary injury mechanism in oxLDL-treated DRG neurons.
This activation of NAD(P)H oxidase is mediated via LOX-1
signaling, since blocking LOX-1 abrogates oxLDL-induced
DRG neuron injury. Our data agree with studies showing
LOX-1–mediated activation of NAD(P)H oxidase in vascu-
lar endothelial cells through recruitment of NAD(P)H
oxidase subunits (50). Collectively, these data demon-
strate a pivotal role for NAD(P)H oxidase in the injury of
DRG neurons and the progression of neuropathy (51).
This study demonstrates a mechanism by which dyslip-
idemia produces DRG neuron injury that may underlie
emerging clinical evidence that dyslipidemia is an indepen-
dent risk factor for diabetic neuropathy. The data suggest
why glycemic control alone is insufﬁcient to prevent
complications in type 2 diabetes and argue for combina-
tion therapies targeting multiple metabolic imbalances and
receptor-mediated signaling that leads to oxidative injury.
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